Form 4: Perspective Therapeutics CEO Acquires 8,000 Shares in Open Market Transaction

Perspective Therapeutics CEO, Johan M. Spoor, purchased 8,000 shares of common stock at a weighted average price of $3.7665 on December 4, 2024.

Summary

• Johan M. Spoor, CEO of Perspective Therapeutics, Inc., acquired 8,000 shares of common stock on December 4, 2024.
• The shares were purchased at a weighted average price of $3.7665 per share.
• The transactions occurred at prices ranging from $3.7596 to $3.7700.
• Following the transaction, Mr. Spoor directly owns 36,257 shares.
• Mr. Spoor also indirectly owns 5,400 shares through his IRA, 12,600 shares through his spouse's IRA, and 1,000 shares through a child.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it reports a routine insider transaction. The CEO's purchase could be seen as a positive sign, but it's not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
• The purchase increases the CEO's direct stake in the company.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific industry trend.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• The filing is consistent with SEC regulations for reporting changes in beneficial ownership.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased investment in the company.

Key Dates

Keywords

insider trading, stock purchase, CEO, Perspective Therapeutics, CATX, common stock, beneficial ownership